Evaxion announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA^® (NCT05309421).

Evaxion is pleased to announce the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from Evaxion’s preclinical EVX-B1 vaccine candidate against Staphylococcus aureus (S. aureus).

Evaxion today provides a business update and announces full year 2023 financial results.

Evaxion hosts a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform.

Evaxion announces that it will host a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform on March 19, 2024, at 14:00 - 18:00 CET / 8:00 a.m. - 12:00 a.m. EST.

Evaxion announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA). The vaccine development project combines both organizations' unique capabilities and know-how.

Evaxion announces that on February 05, 2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2).

Evaxion announces the pricing of a public offering of an aggregate of 3,750,000 of its American Depositary Shares (“ADSs”) (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS (or pre-funded warrant in lieu thereof) and accompanying warrant.

Evaxion announces an expanded commitment to developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens, named Endogenous Retroviruses (ERVs).